CeaproTSXV: CZO

Ceapro announces 2005 third quarter financial results

· Issued by Ceapro via CNW
EDMONTON, Nov. 9 /CNW/ - Ceapro Inc. (TSX-V: CZO) today released its
third quarter financial results for 2005. Ceapro produced solid financial
results with strong performance in sales and improvements in margins. Sales
increased 25% to $2 million for the first time over nine months, marking a
significant milestone. However, costs associated with CeaProve(TM) affected
the overall financial results producing a net loss of $178,000 for the nine
month period ending September 30, 2005.
"We are pleased with our quarterly financial results especially the
continued growth in sales of active ingredients and the great strides we have
made in the development of CeaProve(TM), identifying new applications in the
areas of diabetes screening," stated Dr. Mark Redmond, President and CEO of
Ceapro. "Our financial outlook for 2005 is positive, having received sales
orders to achieve our best annual sales performance to date."

Third Quarter Highlights

-   Sales climbed 87% to $654,000
-   Sales of active ingredients up 185%
-   Income from operations of $35,000
-   Net loss of $125,000
-   Working capital improved to $125,000
-   Gross margins increased to 64% from 36%, reflecting changes in
    product mix, higher sales of active ingredients, and improved plant
    efficiency

Outlook

The initiatives undertaken last year have resulted in an increase in
sales, and our second quarter of 2005 was the highest revenue quarter in
Ceapro's history, and Ceapro followed that up with the second highest active
ingredient sales this quarter, which allowed us to match our active ingredient
sales that Ceapro had in 2003 and surpass 2004 active ingredient sales. Ceapro
generated income from operations in the third quarter of $35,000, and there
was significant improvement in our working capital. The expansion of sales to
existing customers, and the introduction of new products to new customers have
boosted sales of active ingredients. Ceapro has continued to make advances
with major exports despite the strengthening of the Canadian dollar over the
last year and few years.
Ceapro have made strides in the development of CeaProve(TM), our diabetes
screening product, identifying new applications in the areas of diabetes
monitoring and drug dosage determination. The signing of new distribution
agreements for veterinary therapeutic products in Asia and Canada, the
development of new veterinary therapeutic products and their addition to the
Japan distribution agreement all pave the way for increased sales in 2006.
Ceapro will continue to pursue additional financings to fund ongoing
working capital requirements and to secure the financial resources required to
support the expected increases in the volume of sales of existing products,
the introduction of new products to existing and new markets, and the further
development of new technology. We intend to implement our operating plans in a
measured and responsible manner. We caution that additional investments may be
required to continue to grow the business and product lines and availability
of these additional investments may affect the pace of growth.

About Ceapro Inc.

Ceapro Inc., an innovation-driven biotechnology company, develops and
commercializes organic products for medical, cosmetic, and animal health
industries using proprietary technology and natural, renewable resources.
Based in Edmonton, Alberta, Ceapro is one of Alberta Venture's Fastest Growing
Companies for 2004 and 2005 and is one of Profit Magazine's Next 100
Companies. Ceapro is also the recipient of the ASTech Award for Outstanding
Commercial Achievement for companies with annual sales of less than
$25 million. Ceapro's shares trade on the TSX Venture Exchange under the
symbol CZO. To learn more about Ceapro, log on to our website at
www.ceapro.com. Shares Outstanding: 36,757,485, Recent Close: $0.45.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the forward-
looking statements contained herein are reasonable, it can give no assurance
that the Company's expectations are correct. All forward-looking statements
are expressly qualified in their entirety by this cautionary statement.

<<
CEAPRO INC.
Consolidated Balance Sheets


                                              September 30    December 31
                                                  2005            2004
                                               (Unaudited)     (Audited)
-------------------------------------------------------------------------
ASSETS
CURRENT ASSETS
  Cash                                         $   119,017   $    96,266
  Accounts receivable                              375,922       375,160
  Inventories                                      231,628       345,424
  Prepaid expenses and deposits                    105,319        66,473
  Deferred charges                                       -        50,000
-------------------------------------------------------------------------
                                                   831,886       933,323

RESTRICTED CASH FOR THE PURCHASE OF
 PROPERTY AND EQUIPMENT                              3,515        64,430

PROPERTY AND EQUIPMENT (NET OF
 ACCUMULATED AMORTIZATION)                         674,239       720,067
-------------------------------------------------------------------------
                                               $ 1,509,640   $ 1,717,820
-------------------------------------------------------------------------
-------------------------------------------------------------------------
LIABILITIES
CURRENT LIABILITIES
  Accounts payable and accrued liabilities     $   408,423   $   713,201
  Deferred revenue                                       -        80,000
  Callable debt                                     92,367       122,296
  Current portion of long-term debt                 32,788        28,234
  Current portion of convertible debentures              -        17,510
  Current portion of royalties payable             173,748       104,498
-------------------------------------------------------------------------
                                                   707,326     1,065,739

Long-Term Debt                                     446,906       471,766

Royalties Payable                                   78,778        66,249
-------------------------------------------------------------------------
                                                 1,233,010     1,603,754
-------------------------------------------------------------------------
SHAREHOLDERS' EQUITY

SHARE CAPITAL                                    2,338,227     1,995,443
CONTRIBUTED SURPLUS                                121,329       121,997
DEFICIT                                         (2,182,926)   (2,003,374)
-------------------------------------------------------------------------
                                                   276,630       114,066
-------------------------------------------------------------------------
                                               $ 1,509,640   $ 1,717,820
-------------------------------------------------------------------------



CEAPRO INC.
Consolidated Statements of Net (Loss) Income and Deficit
Unaudited

                             Nine Months Ended          Quarters Ended
                               September 30              September 30
                             2005         2004         2005         2004
-------------------------------------------------------------------------
Revenue
  Sales               $ 2,074,388  $ 1,657,754  $   654,065  $   349,080
  Cost of goods sold      876,743      836,776      236,591      223,271
-------------------------------------------------------------------------

  Gross margin          1,197,645      820,978      417,474      125,809
  Royalties, licenses,
   and product
   development fees        80,000      292,758            -       65,258
-------------------------------------------------------------------------

                        1,277,645    1,113,736      417,474      191,067
-------------------------------------------------------------------------
Expenses
  General and
   administration         728,329      633,680      206,164      215,043
  Royalties               245,358      225,650       68,236       45,984
  Sales and marketing     174,261       95,791       54,675       35,142
  Amortization            119,667       62,481       40,847       22,752
  Interest on long-term
   and callable debt       35,110       10,583       12,584        5,885
  Interest on convertible
   debentures and other     2,452        5,775          105        1,714
-------------------------------------------------------------------------

                        1,305,177    1,033,960      382,611      326,520
-------------------------------------------------------------------------

Income (loss) from
 operations               (27,532)      79,776       34,863     (135,453)
-------------------------------------------------------------------------

Other income (expenses)
  Research and product
   development           (368,702)    (248,165)    (141,475)    (136,828)
  Loss on disposal of
   property and
   equipment                    -      (12,389)           -       (7,218)
  Other income
   (expenses)             216,682     (139,120)     (17,957)     (81,741)
-------------------------------------------------------------------------

                         (152,020)    (399,674)    (159,432)    (225,787)
-------------------------------------------------------------------------

Income (Loss) before
 income taxes            (179,552)    (319,898)    (124,569)    (361,240)

Income Taxes
  Current                (104,000)           -      (28,000)           -
  Reduction as a
   result of applying
   non-capital
   losses carried
   forward against
   the current period's
   taxable income         104,000            -        28,000           -
-------------------------------------------------------------------------

NET (LOSS) INCOME FOR
 THE PERIOD              (179,552)    (319,898)    (124,569)    (361,240)

Deficit, beginning of
 period                (2,003,374)  (1,605,637)  (2,058,357)  (1,564,295)
-------------------------------------------------------------------------

Deficit, end of
 period               $(2,182,926) $(1,925,535) $(2,182,926) $(1,925,535)
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Net (loss) income
 per share:
  Basic               $    (0.005) $    (0.009) $    (0.003) $    (0.010)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
  Diluted             $    (0.005) $    (0.009) $    (0.003) $    (0.010)
-------------------------------------------------------------------------
-------------------------------------------------------------------------


    CEAPRO INC.
Consolidated Statements of Net (Loss) Income and Deficit
Unaudited

                             Nine Months Ended          Quarters Ended
                               September 30              September 30
                             2005         2004         2005         2004
-------------------------------------------------------------------------
Revenue
  Sales               $ 2,074,388  $ 1,657,754  $   654,065  $   349,080
  Cost of goods sold      876,743      836,776      236,591      223,271
-------------------------------------------------------------------------
  Gross margin          1,197,645      820,978      417,474      125,809
  Royalties, licenses,
   and product
   development fees        80,000      292,758            -       65,258
-------------------------------------------------------------------------
                        1,277,645    1,113,736      417,474      191,067
-------------------------------------------------------------------------
Expenses
  General and
   administration         728,329      633,680      206,164      215,043
  Royalties               245,358      225,650       68,236       45,984
  Sales and marketing     174,261       95,791       54,675       35,142
  Amortization            119,667       62,481       40,847       22,752
  Interest on long-term
   and callable debt       35,110       10,583       12,584        5,885
  Interest on
   convertible
   debentures and other     2,452        5,775          105        1,714
-------------------------------------------------------------------------
                        1,305,177    1,033,960      382,611      326,520
-------------------------------------------------------------------------
Income (loss) from
 operations               (27,532)      79,776       34,863     (135,453)
-------------------------------------------------------------------------
Other income (expenses)
  Research and product
   development           (368,702)    (248,165)    (141,475)    (136,828)
  Loss on disposal of
   property and
   equipment                    -      (12,389)           -       (7,218)
  Other income
   (expenses)             216,682     (139,120)     (17,957)     (81,741)
-------------------------------------------------------------------------
                         (152,020)    (399,674)    (159,432)    (225,787)
-------------------------------------------------------------------------
Income (Loss) before
 income taxes            (179,552)    (319,898)    (124,569)    (361,240)

Income Taxes
  Current                (104,000)           -      (28,000)           -
  Reduction  as a
   result of applying
   non-capital
   losses carried
   forward against
   the current period's
   taxable income         104,000            -        28,000           -
-------------------------------------------------------------------------
NET (LOSS) INCOME FOR
 THE PERIOD              (179,552)    (319,898)    (124,569)    (361,240)

Deficit, beginning of
 period                (2,003,374)  (1,605,637)  (2,058,357)  (1,564,295)
-------------------------------------------------------------------------
Deficit, end of
 period               $(2,182,926) $(1,925,535) $(2,182,926) $(1,925,535)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Net (loss) income
 per share:
  Basic               $    (0.005) $    (0.009) $    (0.003) $    (0.010)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
  Diluted             $    (0.005) $    (0.009) $    (0.003) $    (0.010)
-------------------------------------------------------------------------
-------------------------------------------------------------------------



CEAPRO INC.
Consolidated Statements of Cash Flows
Unaudited

                             Nine Months Ended          Quarters Ended
                               September 30              September 30
                             2005         2004         2005         2004
-------------------------------------------------------------------------
Operating Activities
  Net (loss) income
   for the period     $  (179,552) $  (319,898) $  (124,569) $  (361,240)
  Items not affecting
   cash
    Amortization          119,667       62,481       40,847       22,752
    Loss on disposal
     of property and
     equipment                  -       12,389            -        7,218
    Stock based
     compensation          49,945       18,434       48,147          572
-------------------------------------------------------------------------

                           (9,940)    (226,594)     (35,575)    (330,698)

Changes in Non-Cash
 Working Capital Items
  Accounts receivable        (762)     382,165      220,769      684,458
  Inventories             113,796     (248,227)      38,796     (190,821)
  Prepaid expenses and
   deposits               (38,846)      (7,544)     (53,313)      54,481
  Deferred charges         50,000            -       75,000            -
  Accounts payable and
   accrued liabilities   (304,778)     124,926     (281,959)    (106,143)
  Deferred revenue        (80,000)           -            -            -
  ------------------------------------------------------------------------
-
                         (270,530)      24,726      (36,282)     111,277
-------------------------------------------------------------------------

Investing Activities
  Purchase of property
   and equipment          (73,839)    (327,280)     (11,035)    (269,158)
  Restricted cash for
   the purchase of
   property and equipment  60,915            -       11,035            -
-------------------------------------------------------------------------

                          (12,924)    (327,280)           -     (269,158)
-------------------------------------------------------------------------

Financing Activities
  Repayment of long-term
   debt                   (20,306)     153,675       (7,755)     193,098
  Repayment of callable
   debt                   (29,929)           -      (10,163)           -
  Repayment of
   convertible debenture  (20,000)     (10,000)           -      (10,000)
  Proceeds from issuance
   of share capital       204,800            -            -            -
  Proceeds from exercise
   of stock options        89,861       43,587       80,361       16,537
  Increase (decrease) in
   royalties payable       81,779      (29,546)     (17,460)     (77,134)
-------------------------------------------------------------------------

                          306,205      157,716       44,983      122,501
-------------------------------------------------------------------------

Increase (decrease) in
 cash                      22,751     (144,838)       8,701      (35,380)
Cash at beginning of
 period                    96,266      248,443      110,316      138,985
-------------------------------------------------------------------------

Cash at end of period $   119,017  $   103,605  $   119,017  $   103,605
-------------------------------------------------------------------------
-------------------------------------------------------------------------

Supplementary
 information:
  Interest paid       $    41,014  $    14,233  $    12,689  $     4,304

>>

%SEDAR: 00010110E

Ceapro on 6ix

Story so far

Earlier from Ceapro

Later from Ceapro

All Ceapro news releases